Session #1: Paths From Assessments to Functional Labs Examples of how countries and companies construct labs in three regions Activities at those labs.

Slides:



Advertisements
Similar presentations
Biological Agents.
Advertisements

Stuart D. Blacksell MPH, PhD, RBP Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand. Wellcome Trust-Mahosot Hospital-Oxford Tropical.
The Way Ahead How can we make a difference for good as a result of this meeting? What problems are we trying to solve? Laboratory Capacity? Clinical/Diagnostics,
Requirements for and Challenges associated with BSL4 laboratories Dr Greg Smith Microbiological Security Manager Australian Animal Health Laboratory Geelong,
European Antibiotic Awareness Day 2013, 18 November 2013 European Antibiotic Awareness Day 2013 * Joining efforts to avoid a post-antibiotic era [Name.
Highly Pathogenic Avian Influenza IN EGYPT Presentation by Prof. Dr. Hamed Samaha CVO, GOVS HPAI Technical Meeting Rome, June.
Regional Health Focus Rome | 27 – 29 June |1 | Health Focus WHO Regional Perspective FAO/ OIE/ WHO Technical Meeting on Highly Pathogenic Avian.
Organization of African Unity/Inter African Bureau for Animal ResourcesPan African Programme for the Control of Epizootics (PACE) Slide No.1 FAO REGIONAL.
Vaccination Campaigns for HPAI in China Huang Baoxu China Animal Health and Epidemiology Centre Beijing.
Protecting American Agriculture 1 Avian Influenza: Agricultural Perspectives & Interventions December 14, 2005.
Public and Private Interests in Animal Research LAT Chapter 1.
Stuart D. Blacksell MPH PhD RBP Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.
U.S. Department of Defense Drug and Vaccine Development
SARS Epidemic: A Global Challenge Bong-Min Yang, PhD & Sung-il Cho, MD, PhD of School of Public Health Seoul National University.
ERIKA BARRETT TECHNICIAN, BIOLOGICAL SAFETY OFFICE OF RADIATION, CHEMICAL & BIOLOGICAL SAFETY FRIDAY, OCTOBER 3.
O PERATING A BSL-3 F ACILITY IN K OREA T HE IVI E XPERIENCE INTERNATIONAL WORKSHOP ON ANTICIPATING BIOSECURITY CHALLENGES OF THE GLOBAL EXPANSION OF HIGH.
Towards a global plan to fight against bioterrorism in synergy with Russian Federation Novosibirsk
Bioterrorism MLAB 2434: Microiology Keri Brophy-Martinez.
Biosafety and the Southeast Asian Clinical Infectious Diseases Network (SEAICRN) Rogier van Doorn Clinical Microbiologist Wellcome Trust Major Overseas.
Pakistan National Accreditation Council. Biorisk Management.
Vaccination Strategy Against HPAI (H 5 N 1 ) in Egypt by Ehab El Masry General Organization for Veterinary Services (GOVS) Tel:
PANDEMIC RISK. 3 pre-requisites for a Pandemic 1. The emergence of a new virus strain with no circulating immunity within the human population 2. The.
African Science Academy Development Initiative
Biosafety and Biosecurity Challenges in the Caribbean Region Valerie Wilson Caribbean Med Labs Foundation Anticipating Global Biosecurity Challenges Istanbul,
The Global Threat of Infectious Diseases Background 20 th Century Re-Emergence of Infectious Diseases - Newly recognized diseases - Known diseases -
“A world that is safe and secure from the accidental or deliberate release of animal pathogens, including zoonoses.” Released in Jan
Local Recombinant DNA Oversight Mass Biotech Council Series Enforcement of the Cambridge Recombinant DNA Technology Ordinance Cambridge Biosafety Committee.
1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.
To Fight EID, Think Global, Act Local Our response to Emerging Diseases is considered on a global basis, but implementation is regional – The risk and.
Biosafety/ Biosecurity in Georgia Lela Bakanidze, Ph.D. National Center for Disease Control and Medical Statistics of Georgia Scientific Networking and.
Safety organization and training. The biosafety officer and biosafety committee A safety policy, A safety manual, and Supporting programmes for their.
Protecting American Agriculture 1 Avian Influenza: Agricultural Perspectives & Interventions March 2006.
1 OIE Response to the HPAI Threat in the SADC Region 1 st SADC Meeting on Avian Influenza Pretoria, South Africa 7-9 March 2006 Sub Regional Representation.
Food and Drug Administration
Third OIE Global Conference on Animal Welfare Kuala Lumpur, Malaysia The OIE PVS Pathway Dr. Mariela Varas OIE International Trade Department.
Laboratory Twinning to improve disease security world wide Keith Hamilton Scientific and Technical Department World Organisation for Animal Health (OIE)
IFBA’s Biocontainment Engineering Network Istanbul. July, 2011 K. Ugwu Co-chair IFBA Biocontainment Engineering Working Group.
Result of gap analysis and framework of action required in coming five months August rd Meeting of National Influenza Centres in the Western.
Avian Influenza When avian influenza hits will science have an efficient vaccine?
A Potential Influenza Pandemic: Possible Macroeconomic Effects and Policy Issues Julie Somers Congressional Budget Office Prepared for the Ninth Annual.
Communicable Disease Surveillance and Response, WHO Avian Influenza Credit: WHO Viet Nam.
High Containment Laboratories in Ukraine - Local Resources and Regulations Olena Kysil *National Taras Shevchenko University of Kyiv **Palladin.
Conclusions 3 rd Meeting of National Influenza Centres in the Western Pacific and South East Asia Regions 18 – 20 August 2009 Beijing, China.
Sector Working Group General Directorate of Veterinary services and Animal Health March /2011.
Sudan EPI Benefits From Polio Eradication Program M&RI Annual Partners Meetings Washington D.C September 2015 Sudan EPI Benefits From Polio Eradication.
ASDPE International Health Regulations (IHR 2005) Laboratory and Zoonosis update Dr Richard Brown, WHO Thailand Workshop on Laboratory Diagnosis for Zoonotic.
Informational Webinar Today’s Webinar Objectives:  Describe the Role of the National Ebola Training and Education Center (NETEC)  Explore netec.org.
National Influenza Centres in SEA Region Dr Rajesh Bhatia / Dr Oommen John WHO Regional Office for South-East Asia New Delhi 5 th Meeting of NIC in Western.
Ebola preparedness and Response in Lao PDR. Outline Objective The preparedness contingency plan Phase 1: Preparedness Phase 2: Contingency for response.
1 Outcome of the 4 th Global Animal Health Conference (GAHC) June 2015 Bettye K. Walters, DVM US Food and Drug Administration
Prof. William Bazeyo One Health Central and Eastern Africa (OHCEA) One Health Conference –Libreville, Gabon 12 th -15th November 2012.
Egypt Current Situation Animal Health Situation, Ongoing Programs & Future Plans Diagnostic facilities workgroup 1 Dr. Shahin Bayoumi.
Ratification of BWC BWC Expert Group, Republic of Korea Compendium of National Activities in Korea: Measures to Improve Biosafety and Biosecurity Hei Chan.
NIH Guidelines for Research Involving rDNA Molecules (NIH Guidelines) and Institutional Biosafety Committees.
SARS: International Coordination SARS: International Coordination and Collaboration James W. LeDuc, Ph.D. Director, Division of Viral and Rickettsial Diseases.
Safety Management Systems Session Four Safety Promotion APTA Webinar June 9, 2016.
Animal Health Status in Jordan All Animal Diseases are obligatory notifiable and controlled under MOA law and regulation. All Animal Diseases are obligatory.
Trends and dynamics of HPAI - epidemiological and animal health risks Technical Meeting on HPAI and Human H5N1 Infection Rome, Italy, June 27-29, 2007.
Egyptian Nuclear and Radiological Regulatory Authority (ENRRA)
Keith Hamilton OIE Scientific and Technical Department, OIE Paris
An important tool in the prevention of animal diseases
The role of the OIE in biological threat reduction
Epidemiology of Foot and Mouth Disease in Georgia
The Role of NICs in Influenza Surveillance
OIE Laboratory Twinning
Avian Influenza Prevention and Control from an OIE Perspective
Office International des Épizooties
Office International des Épizooties
Workshop on the Revised WHO Guidance
Presentation transcript:

Session #1: Paths From Assessments to Functional Labs Examples of how countries and companies construct labs in three regions Activities at those labs Effectiveness of the labs to meet their original objective Lessons learned during lab operation Rapporteurs: Fran Sharples, Ben Rusek, and Alison Hottes

Breakout #1: Eastern Asia Fran Sharples NAS Staff

Mahidol Oxford Tropical Medicine Research Unit (MORU) Major labs in Bangkok, Vientiane MORU funding imperative is to follow BMBL5, US Select Agent rules, Thai law Requires full time biosafety administrator, registered biosafety professional, 7 biosafety site representatives Requires robust induction procedure and documented competency; dual use awareness; training by experts with regular refreshers Had to create baseline inventory, have catalogued 20,000 samples from freezers over last 3 years Need to rethink some aspects, e.g., in tropical climate, wasteful to pump cool, dry air outside Engineering and technology choices should be based on risk assessments: Is BSL3 really needed? Could BSL2 with some upgrades work instead?

International Vaccine Institute, South Korea Non-profit international with HQ in Seoul under UN Develop Program Subject to Korean law on highly dangerous pathogens Construction began 2007, certified by Korean CDC in 2009, opened in 2010, has operated for one year Operates under internal regulations in BSL3 manual and 19 SOPs Internal approval system: Institutional Biosafety Committee for research and General Manager for access Training to create and nurture biosafety culture for both lab workers aqnd maintenance staff Maintenance: daily/weekly/monthly/annual inspections Alarm system to detect malfunction emergencies Annual revalidation in 2011

Central Biocontainment Laboratory, Bangkok, Thailand Supported by University medical centers and Thai Red Cross Need to provide safe environment for working with bioagents (SARS, bird flu, swine flu) Operated since 2008 Working group of 5 experienced members, one full time staff for facility and equipment, regular maintenance Efforts to sustain and improve Obstacles: costs very high, supported by faculty of medicine so far

Conclusion East Asia a hotbed of emerging and re-emerging infectious diseases At least 45 BSL3 LABS in southeast Asia Many east Asian countries low resource settings: Laos, Cambodia, Vietnam, Thailand For many labs in these countries, are questions about standards, management, training, security, lack of biosafety professionals, etc. Many also lack national legislation or have laws that are poorly enforced and/or understood. (Does not apply to Singapore, Korea, some Thai law). Money to build labs is easy, money for maintenance is hard to come by.

Breakout #2: Africa Ben Rusek NAS Staff

Veterinary Serum and Vaccine Research Institute (VSVRI) Located in Cairo, Egypt Vaccine production facility for avian flu, FMD, sera and diagnostic reagents and research in these areas Part of the response to the Egyptian avian flu outbreak Created BSL3 lab out of existing lab due to the difficulty of getting a license for a new site, construction will be complete in three months Will be a fully functional BSL3 facility when online Currently developing biosafety training program for lab workers

Morocco Biopharma Research Lab State lab created in Used for bacterial fermentation, diagnostics and animal disease surveillance, vaccine production, and culture collection. Has helped keep Morocco free from FMD since 1998 although FMD is endemic in the region (maintains 2 million doses as concentrated inactivated antigen that could be manufactured within two days). Plans to upgrade to GMP standards to improve production and quality control and expand the facilities at the current location This would include an upgrade to the lab buildings from centralized to terminal HEPA filters and improve fluid distribution and waste treatment. Eventually build a new laboratory according to international standards away from the current residential area location.

The International Centre of Medical Research of Franceville Gabon: CIRMF Primarily gov funded lab has isolated 16 of 18 strains of Ebola CIRMF remote location is close to emerging infections (500 km from capital, all facilities onsite) Emergency BSL3+ took 2 years to build in 1997 after Ebola outbreak in Gabon, BSL4 completed in 2011 and took 7 years Today operates BSL3, ABSL3 and primate facility and BSL4 glovebox Remote location makes maintenance a problem

Conclusion North Africa is an international crossroads and Central Africa is a hotbed of emerging infectious diseases so the location of containment labs in the region is especially important Although the three labs presented in Egypt, Morocco and Gabon would be considered to be in “developing” countries all are well funded For these labs partnership with other countries and federal sponsorship are important for sustainment These labs are fulfilling their research and public health goals but require good leadership to implement projects and programs in the future. Again largest issues are funding for maintenance and training. Important to design the maintenance plan for a facility as it is being designed and built Might be useful to have a group that certifies BSL3 equipment in Africa

Breakout #3: Eastern Europe and Western Asia Alison Hottes NAS Staff

Pendik Veterinary Control and Research Institute (Turkey) Founded in 1894 and moved to current location in 1912 Started by producing cattle plague serum Currently national reference lab for some animal diseases and has responsibility for animal diseases in local region Produces vaccines, serums, antigens In response to avian influenza in domestic and wild poultry, Turkey assessed needs –Decided to add BSL3 capabilities to Pendik Currently waiting for equipment placement and personnel training

Chumakov Institute of Poliomyelitis & Viral Encephalitides of Russian Academy of Medical Sciences Founded 1955 to combat poliomyelitis –Produced vaccines that lead to successful eradiation of poliomyelitis in Russia (since reintroduced) Focus changing to match current public health threats such as hepatitis B and hemorrhagic fever with renal syndrome Recently removed old infrastructure and updated virus collections Currently holds Containment BSL2 Certification (Russian system)—need to pay to maintain certification 6 workers, including presenter, have been infected by a hantavirus or an arenavirus during laboratory research

Georgian Central Public Health Reference Laboratory U.S. supporting as part of Biological Threat Reduction Program and will maintain long-term presence Will serve as regional reference lab –Promote public and animal health through infectious disease detection, epidemiological surveillance, and research for the benefit of Georgia, the Caucasus region, and the global community. Half BSL3-capable, half BSL2-capable Animal and human wings Currently training Georgian locals Expect certification by end of the year

Planned Kyrgyz Republic Lab Canada committed $1 billion to Global Partnership including $100 million for biological non-proliferation Searched for projects in former Soviet Union with large impact –Kyrgyz Republic has endemic diseases of terrorist concern (e.g., FMD, anthrax), large pathogen collections, and decaying facilities Designed lab –Animal and human facilities –Central reference lab –Attempt to use local markets and trades –Involved scientists, government, community, and designers from the beginning Lab currently on hold due to Krygyz Republic politics

Lessons Learned Uncertainty leads to overdesign  do full needs assessment first and expect things to evolve Involve and inform everyone from the start including community, local and national government, collaborators, scientists, designers, engineers, contractors, and certifiers Only accept contractors and sub-contractors with containment lab experience

Issues Raised When should pathogen collections be destroyed? Preserved? Should the decision to build a lab be a national or international decision? Is there a way to certify workers as BSL3- competent? Should animal and human work be combined in a single lab? –Cost effective –Groups historically are separate, but forced interactions can be productive (One Health)